FDA Approved: DOXORUBICIN HYDROCHLORIDE — Supplemental Application (Fresenius Kabi USA, LLC)

View source ↗

Summary

FDA approved a supplemental application for doxorubicin hydrochloride (Fresenius Kabi USA, LLC) under anANDA to support its generic product.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Acute Myeloid Leukemia
• Bladder Cancer
• Breast Cancer
• Hodgkin Lymphoma
• Melanoma
• Non-hodgkin Lymphoma
• Soft Tissue Sarcoma

Drugs mentioned

• DOXORUBICIN HYDROCHLORIDE (Doxorubicin hydrochloride)

Snippet

SUPPL AP for DOXORUBICIN HYDROCHLORIDE (DOXORUBICIN HYDROCHLORIDE)